CHATSWORTH, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- XYRA Corp., a subsidiary of Cavitation Technologies, Inc. (OTCQB: CVAT), an AI-driven, quantum-secure payment network uniting remittances, fintech, and crypto assets under one tokenized, compliant infrastructure, today announced that it has secured a license agreement that will enable XYRA to accept and process digital assets in real time, such as USDC stablecoin, as well as leading cryptocurrencies like Bitcoin, Ethereum, and Tether, with instant conver ...

Core Insights - Cadrenal Therapeutics, Inc. has appointed Dr. Lee Scott Golden as an independent director to its Board of Directors, effective immediately [1][3] - Dr. Golden brings over 25 years of experience in the biopharmaceutical industry, particularly in cardiovascular medicine and anticoagulation therapy [2][3] - The company aims to develop novel anticoagulants to address significant unmet needs in both acute and chronic anticoagulation therapy [4] Company Overview - Cadrenal Therapeutics focuses on developing innovative biopharmaceutical products that improve anticoagulation therapy by providing greater predictability, stability, and fewer bleeding complications [4] - The company currently has two clinical-stage assets: tecarfarin, an oral vitamin K antagonist for chronic use, and frunexian, a parenteral small-molecule Factor XIa antagonist for acute hospital settings [4] - The mission is to reshape standards of care in anticoagulation by targeting underserved patient populations [4]

Core Insights - Clearmind Medicine Inc. has announced significant progress in its FDA-approved Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic oral therapy targeting Alcohol Use Disorder (AUD) [1][2][3] Group 1: Clinical Trial Progress - The company reported positive top-line results from the first cohort of six participants, dosed at prestigious institutions including Johns Hopkins University and Yale University [4] - The independent Data and Safety Monitoring Board (DSMB) unanimously approved the continuation of the clinical trial after an interim safety review [5] - Enrollment has commenced at a new clinical site in Israel, Tel Aviv Sourasky Medical Center, enhancing patient recruitment efforts [6] Group 2: Market Context and Impact - AUD affects over 28 million adults in the U.S., incurring societal and economic costs exceeding $249 billion annually, highlighting the need for effective treatments [3] - Current treatment options for AUD are limited in efficacy and accessibility, positioning Clearmind's CMND-100 as a potentially transformative solution [3] Group 3: Company Overview - Clearmind is focused on developing novel neuroplastogen-derived therapeutics to address significant health issues, including AUD [7] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans for further acquisitions [8]

Core Insights - AIM ImmunoTech will participate in the Virtual Investor Closing Bell Series on December 4, 2025, featuring CEO Thomas K. Equels [1] - The discussion will focus on AIM's clinical and regulatory strategy for its lead drug Ampligen, particularly the DURIPANC clinical trial in collaboration with AstraZeneca for metastatic pancreatic cancer [2] - The importance of a completed Phase 2 clinical trial with Merck, showing the combination of Ampligen and Keytruda was well-tolerated and beneficial for advanced recurrent ovarian cancer, will also be highlighted [2] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [4] - The company's lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator [4]

Core Viewpoint - Intercont (Cayman) Limited has announced a strategic partnership with CINCO INTERNATIONAL HONGKONG LIMITED to enhance its shipping segment and deliver stable, multi-year cash flow while aligning with the industry's shift towards low-carbon operations [1][2]. Company Overview - Intercont (Cayman) Limited is a global carbon-neutral shipping company focused on providing efficient and environmentally friendly transportation solutions through innovative business models and technology [8]. - CINCO INTERNATIONAL HONGKONG LIMITED is recognized for its operational excellence in the ro-ro shipping sector, which is crucial for the partnership's success [2]. Partnership Details - The partnership aims to expand NCT's shipping segment in response to rising market demand, particularly in the context of new energy vehicles and cross-border e-commerce [5]. - The transaction is expected to generate approximately US$118.25 million in cumulative contract revenue and an estimated net profit of US$88.96 million [6]. Industry Context - Ro-ro vessels are designed for transporting automobiles and wheeled cargo, offering a low-carbon, high-efficiency solution that significantly reduces energy use compared to conventional cargo ships [3]. - The global shipping industry is transitioning towards low-carbon operations, with ro-ro vessels positioned to meet the increasing demand for rapid transportation solutions [5]. Environmental Impact - Ro-ro ships feature advanced technologies such as LNG dual-fuel engines and onboard solar panels, which can reduce carbon output per voyage by an estimated 30% [3]. - The partnership enhances NCT's commitment to executing its carbon-neutral strategy while providing diversified green transport solutions [7].

Deploying on Cocoon’s Launch Day Positions AlphaTON at the Forefront of the Decentralized AI Revolution as Telegram’s Cocoon AI Is Set to Surpass OpenAI's User BaseDover, Delaware, Dec. 01, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (NASDAQ: ATON), the world's leading technology public company scaling the Telegram super app, with an addressable market of 1 billion monthly active users, today announced the successful deployment of its first fleet of Nvidia B200 GPUs to Telegram's Cocoon AI network, marki ...

JINHUA, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SALI, a global leader in power tool accessories, today launched its "Emerging Market Partnership Program", actively recruiting premium agents across the Middle East, Africa, and Latin America. With 6 products ranking TOP3 and 14 in TOP10 on Amazon US/EU sites, plus proven expertise serving over 1 million professional users in Western markets, SALI offers new partners risk-free supply chain support and high-return brand empowerment to jointly explore the blue ...

Core Insights - Propanc Biopharma has submitted a request for a foreign filing license from Spain for two provisional patents aimed at treating resistant cancer and fibrosis, marking a significant step in its research and development efforts [1][5] - The first patent focuses on methods to treat cancers that have developed resistance to chemotherapy and radiotherapy, addressing the urgent need for new strategies to prevent recurrence and treatment failure [2] - The second patent pertains to compositions and methods for treating fibrosis, which is characterized by excessive scar tissue accumulation and can affect various organ systems, significantly impacting morbidity and mortality [3] Patent Details - The first provisional patent addresses treatment methods for chemotherapy-resistant cancers, highlighting the ongoing high global mortality rates and the necessity for innovative approaches [2] - The second provisional patent represents a novel addition to Propanc's intellectual property portfolio, utilizing the lead product candidate PRP for chronic diseases beyond cancer, particularly focusing on the epithelial-to-mesenchymal transition (EMT) as a therapeutic target [4] Future Plans - The CEO of Propanc, James Nathanielsz, emphasized that the submission of these patents is a pivotal moment for the company, with plans for a Phase 1b, First-In-Human study in 2026 to determine the therapeutic dose of PRP [5] - The company aims to explore the application of PRP across multiple disease conditions in subsequent Phase 2 proof-of-concept studies, positioning it as a novel therapeutic approach that encourages normal cell behavior without the cytotoxic effects of standard treatments [5] Company Overview - Propanc Biopharma is focused on developing innovative treatments to prevent cancer recurrence and metastasis by targeting cancer stem cells through proenzyme activation, with its lead product candidate PRP designed to address the underlying drivers of cancer proliferation [6]

Core Insights - ConnectM Technology Solutions, Inc. has successfully transitioned from the Expert Market to OTCQB, restored its SEC reporting status, and is experiencing revenue growth while developing its Keen Labs platform in the battery and energy storage sectors [1][2][5]. Group 1: Company Progress - The company has executed its plan post-Nasdaq delisting, focusing on current SEC filings, uplisting to OTCQB, revenue growth, and debt reduction [2][4]. - Management has reported double-digit year-over-year revenue growth in each quarter since the Nasdaq delisting, achieving approximately 60% year-to-date revenue growth through Q3 2025 [5][6]. - ConnectM has retired over $10 million in debt and derivative liabilities in 2025, moving from a stockholders' deficit of approximately $50 million to an estimated positive stockholders' equity of around $0.75 million [8]. Group 2: Strategic Developments - The company launched Keen Labs, focusing on AI, industrial IoT, battery systems, and distributed energy platforms, and has made strategic acquisitions to enhance its technology offerings [8][9]. - Acquisitions include Amperics for hybrid battery technology, Geo Impex for an AI-driven data center site, and Air Temp Service Co. and Cambridge Energy Resources Ltd. to expand HVAC services [8]. - A joint venture, StarConnectM LLP, was formed with Star Engineers in India to develop AI-powered connected vehicle platforms [8]. Group 3: Future Outlook - Near- and medium-term priorities include scaling revenue and margins, continuing to reduce liabilities, integrating recent acquisitions, and pursuing targeted M&A in electrification and AI-driven energy infrastructure [9]. - The company is working with ThinkEquity LLC to refine its capital markets strategy and prepare for a potential uplisting to a major U.S. exchange [9].

Core Insights - Yorkville Acquisition Corp. has appointed Steve Gutterman as CEO and Sim Salzman as CFO in connection with the closing of a business combination, which will establish a digital asset treasury company focused on the cryptocurrency token of the Cronos ecosystem (CRO) [1][2] Company Overview - Yorkville Acquisition Corp. is a special purpose acquisition company (SPAC) aiming to merge with established businesses for growth opportunities [8] - Trump Media Group CRO Strategy is focused on strategically investing in digital asset ecosystems and managing CRO [7] Leadership Experience - Steve Gutterman has extensive experience in leading high-growth businesses, overseeing over 40 acquisitions and raising more than $2 billion in capital [2][3] - Sim Salzman has 20 years of finance and accounting experience, with a strong background in high-stakes transactions and digital asset strategy [3] Strategic Vision - The leadership team aims to unlock significant value for shareholders through the aggregation of CRO and effective management of digital assets [2][3] - The business combination is seen as a defining moment for cryptocurrencies and digital asset treasuries, positioning Yorkville Acquisition Corp. uniquely in the market [3] Upcoming Developments - The transition of Gutterman and Salzman into their roles is expected to occur with the closing of the business combination, anticipated in the first quarter of 2026 [4]